Researchers at Central Michigan University published last month their study comparing standard curcumin to Longvida curcumin (lipid-solid microencapsulation) in a mouse model.
These authors studied the anti-inflammatory activity, the beta-amyloid plate formation and the neuronal morphology in different regions of the brain of 5xFAD mice treated with either formulation for 2 and 5 days.
They observed that the Longvida formula has a greater affinity for beta-amyloid plaques compared to standard curcumin extract. These results suggest that the Longvida lipid bilayer facilitates the permeability of curcumin in the brain, i.e. the passage of the Blood-Brain Barrier.
In this study, curcumin significantly reduced neuroinflammation and immunoreactivity in different key brain areas of treated mice. In mice treated with curcumin, there was also a reduction in the formation of beta-amyloid plaques and a decrease in the number of neurons with abnormal morphology.
Treatment with Longvida formula had superior anti-inflammatory, anti-amyloid and neuroprotective effects compared to standard curcumin extract. These results suggest that Longvida curcumin is a more effective and promising formulation as a neuroprotector than standard curcumin extract.
Longvida is the formulation used in Optim Curcuma
Maiti P, Paladugu L, Dunbar GL. Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer’s disease. BMC Neurosci. 2018 Feb 23;19(1):7.